NASDAQ: BLLNBilliontoone Inc Stock
$93.39+1.74 (+1.9%)
Updated Aug 7, 2026
BLLN Price
$93.39
Fair Value Price
N/A
Market Cap
$4.41B
52 Week Low
$61.96
52 Week High
$150.44
P/E
111.18x
P/B
8.21x
P/S
14.01x
PEG
3.74x
Dividend Yield
N/A
Revenue
$397.41M
Earnings
$37.71M
Gross Margin
71.3%
Operating Margin
9.55%
Profit Margin
7.6%
Debt to Equity
0.36
Operating Cash Flow
$45M
Beta
1.83
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
BLLN Overview
BillionToOne, Inc. is a specialized diagnostics company that innovates by precisely quantifying biological data to create advanced molecular diagnostic solutions. Central to their operations is a cutting-edge molecular counting platform, meticulously engineered to identify and measure individual DNA molecules, thereby significantly enhancing the precision of disease detection. Their product portfolio includes: UNITY Complete: A non-invasive prenatal screen that assesses a fetus's risk for aneuploidies, recessive genetic conditions, and fetal antigens, all from a simple maternal blood sample. Northstar Select: A liquid biopsy test designed to pinpoint specific mutations present in tumors, encompassing deletions, insertions, and point mutations. Northstar Response: A diagnostic tool that enables continuous tracking of cancer progression through detailed methylation assessment. Established in 2016, BillionToOne, Inc. conducts its operations from its headquarters located in Menlo Park, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLLN's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Diagnostic & Research
Industry Rating
B
BLLN
Ranked#21 of 41
Ranked#21 of 41
Be the first to know about important BLLN news, forecast changes, insider trades & much more!
BLLN News
Overview
Due Diligence Score
–
Industry Average (28)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLLN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLLN ($93.39) is trading above its intrinsic value of $12.25, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
BLLN is poor value based on its earnings relative to its share price (111.18x), compared to the US market average (13.41x)
P/E vs Market Valuation
BLLN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more BLLN due diligence checks available for Premium users.
Valuation
BLLN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
111.18x
Industry
9.79x
Market
13.41x
BLLN is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
BLLN is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
BLLN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.21x
Industry
4.27x
BLLN is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLLN price to earnings growth (PEG)
For valuing profitable companies with growth potential
BLLN is poor value relative... subscribe to Premium to read more.
PEG Value Valuation
BLLN's financial health
Profit margin
Revenue
$109.4M
Net Income
$8.1M
Profit Margin
7.4%
BLLN's Earnings (EBIT) of $37.95M... subscribe to Premium to read more.
Interest Coverage Financials
BLLN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$729.7M
Liabilities
$192.9M
Debt to equity
0.36
BLLN's short-term assets ($651.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLLN's short-term assets ($651.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLLN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$9.1M
Investing
-$4.0M
Financing
$6.1M
BLLN's operating cash flow ($45.35M)... subscribe to Premium to read more.
Debt Coverage Financials
BLLN vs Diagnostic & Research Stocks
Billiontoone Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.